Prolonged Half-life of Voriconazole in a CYP2C19 Homozygous Poor Metabolizer Receiving Vincristine Chemotherapy: Avoiding a Serious Adverse Drug Interaction

類似資料

• Adverse Interactions between Antifungal Azoles and Vincristine: Review and Analysis of Cases
  著者:: Moriyama, Brad, 等
  出版事項: (2011)
• Pharmacokinetics of Intravenous Voriconazole in Obese Patients: Implications of CYP2C19 Homozygous Poor Metabolizer Genotype
  著者:: Moriyama, Brad, 等
  出版事項: (2013)
• Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole
  著者:: Moriyama, Brad, 等
  出版事項: (2015)
• Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guideline for CYP2C19 and Voriconazole Therapy
  著者:: Moriyama, Brad, 等
  出版事項: (2017)
• A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine
  著者:: Malingré, Mirte M, 等
  出版事項: (2012)